• COVID-19: Endemic Disease
  • Products
    • ASSURE-100 Home Tests
    • ASSURE-100 POC Tests
    • Buy ASSURE-100 Tests
  • News & Updates
  • Contact Us
Buy Tests
  • COVID-19: Endemic Disease
  • Products
    • ASSURE-100 Home Tests
    • ASSURE-100 POC Tests
    • Buy ASSURE-100 Tests
  • News & Updates
  • Contact Us
  • BUY TESTS
Quad-demic Concerns: Managing COVID, Flu, RSV, and Norovirus

Quad-demic Concerns: Managing COVID, Flu, RSV, and Norovirus

by Oceanit | Dec 20, 2024 | Future, Government

Quad-demic Concerns: Managing COVID, Flu, RSV, and Norovirus As the winter season progresses, public health experts are raising concerns about a possible “quad-demic” — the simultaneous spread of four major pathogens: COVID-19, influenza, respiratory...
Guidelines for COVID-19 Vaccinations and Booster Shots in 2024

Guidelines for COVID-19 Vaccinations and Booster Shots in 2024

by Oceanit | Nov 26, 2024 | Government, National News

Guidelines for COVID-19 Vaccinations and Booster Shots in 2024 As the COVID-19 pandemic continues to evolve, staying updated on vaccination guidelines is crucial for personal and public health. In 2024, the Centers for Disease Control and Prevention (CDC) have updated...

Recent Posts

  • New 2025 COVID Vaccine Rules: What They Mean for Americans
  • Summer 2025 COVID Trends: What to Know & How to Stay Safe
  • CDC Updates 2025 COVID-19 Testing, Isolation & Recovery
  • WHO Pandemic Treaty Aims to Prevent Future Health Crises
  • Should You Keep Rapid Tests for Spring & Summer 2025?

Recent Comments

No comments to show.
Copyright 2025 Oceanit Foundry LLC. The ASSURE-100 Rapid COVID-19 Test has not been FDA cleared or approved, but has been authorized by FDA under an EUA. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
[dsm_icon_list list_alignment=”flex-end” _builder_version=”4.27.4″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” list_alignment_last_edited=”on|phone” list_alignment_phone=”center” sticky_enabled=”0″ list_alignment_tablet=”flex-end”][dsm_icon_list_child text=”Privacy Policy” use_icon=”off” url=”/privacy-policy/” _builder_version=”4.27.4″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_text_color=”#e8e8e8″ text_font_size=”12px” text_text_color_last_edited=”off|desktop” global_colors_info=”{}” text_text_color__hover_enabled=”on|desktop” text_text_color__hover=”#1e73be”][/dsm_icon_list_child][/dsm_icon_list]